4.6 Article

Neuromyelitis optica spectrum disorder Patient experience and quality of life

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/NXI.0000000000000580

关键词

-

资金

  1. Guthy-Jackson Charitable Foundation
  2. Alexion Pharmaceuticals, Inc.
  3. Chugai Pharmaceutical Co., Ltd.
  4. Viela Bio
  5. MedImmune Ltd.

向作者/读者索取更多资源

Objective To gain insights into NMOSD disease impact, which may negatively affect QoL of patients, their families, and social network. Methods The current study used validated instruments to assess physical, emotional, and socioeconomic burden of NMOSD on QoL among 193 patients. Results A majority of patients reported an initial diagnosis of a disease other than NMOSD. Overall, two-thirds of patients reported NMOSD as having a strong negative impact on physical health (Short Form-36 [SF-36] score 27.1 +/- 39.1), whereas emotional well-being was relatively unimpaired on average (SF-36 score 54.0 +/- 44.9). A subset of patients reported having the highest category of emotional health despite worse physical health or financial burden, suggesting psychological resilience. Pain (r = 0.61) and bowel/bladder dysfunction (r = 0.41) imposed the greatest negative physical impact on overall QoL. In turn, ability to work correlated inversely with worsened health (r = -0.68). Increased pain, reduced sexual function, inability to work, and reduced QoL had greatest negative impacts on emotional well-being. Dissatisfaction with treatment options and economic burden correlated inversely with QoL. Conclusions Collectively, the current findings advance the understanding of physical, emotional, social, and financial tolls imposed by NMOSD. These insights offer potential ways to enhance QoL by managing pain, enhancing family and social networks, and facilitating active employment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据